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ABSTRACT
CONTEXT AND OBJECTIVE: Many eye diseases involve increased local levels of vascular endothelial growth factor (VEGF), and there are several therapeutic 
strategies for them. Thus, the aim of this study was to evaluate the effectiveness and safety of bevacizumab for treating eye diseases involving increased 
local levels of VEGF, as the assumed pathophysiological mechanism. 
DATA SOURCES: The following databases were systematically searched for evidence: PubMed, CENTRAL (Cochrane Library), Literatura Latino-Americana 
e do Caribe em Ciências da Saúde (Lilacs) and reference lists, without language restrictions. Only randomized controlled trials were included. The primary 
outcome of interest was visual acuity, irrespective of the evaluation method.
DATA SYNTHESIS: A total of 667 eyes in nine randomized trials were included. Meta-analysis showed that the proportion of patients with age-related 
macular degeneration who presented improvements from baseline regarding best-corrected visual acuity was higher among those treated with bevacizumab 
than among those in the photodynamic therapy group (risk ratio, RR, 0.49; 95% confidence interval, CI, 0.31 to 0.78; P = 0.01). 
CONCLUSIONS: The evidence available demonstrates that bevacizumab alone or combined with other treatments is more effective than other options, 
including photodynamic therapy, focal photocoagulation and triamcinolone. The use of bevacizumab instead of photodynamic therapy could reduce 
treatment costs by more than 99% and could significantly increase access to treatment. However, long-term studies are still needed in order to reduce 
uncertainty concerning the safety of this medication for all ocular neovascular diseases in which bevacizumab has the potential to improve visual acuity. 
RESUMO
CONTEXTO E OBJETIVOS: Muitas doenças oculares envolvem o aumento dos níveis locais de fator de crescimento do endotélio vascular (FCEV), uma 
diversidade de estratégias terapêuticas para tais condições. Assim, o objetivo do presente estudo é avaliar a efetividade e a segurança de bevacizumabe 
para o tratamento de pacientes com doença ocular que envolva o aumento dos níveis locais de FCEV, como mecanismo patofisiológico assumido.
FONTE DAS INFORMAÇÕES: Foi realizada busca sistemática pelas evidências disponíveis nas seguintes bases de dados da eletrônicas: PubMed, 
CENTRAL (The Cochrane Library), Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs), além de referências bibliográficas de estudos 
relevantes, sem restrições de língua. Foram incluídos apenas ensaios controlados e aleatórios. Acuidade visual, independentemente do método de 
avaliação, foi considerada o desfecho primário de interesse.
SÍNTESE DOS DADOS: Foi incluído um total de 667 olhos testados em nove ensaios clínicos aleatórios. A metanálise demonstrou que a proporção de 
pacientes com degeneração macular relacionada à idade que melhoraram a acuidade visual foi maior entre os tratados com bevacizumabe do que entre 
os pacientes em terapia fotodinâmica (risco relativo [RR] 0.49, 95% intervalo de confiança [IC] 0,31 a 0,78, P = 0,01).
CONCLUSÕES: A evidência disponível demonstra que bevacizumabe isolado ou combinado com outras terapias é mais eficaz que terapia fotodinâmica, 
fotocoagulação focal e triancinolona. O uso de bevacizumabe em vez da terapia fotodinâmica poderia reduzir os custos do tratamento em mais de 99% e 
aumentar significativamente o acesso ao tratamento. Entretanto, o aspecto de segurança do fármaco ainda necessita ser avaliado por estudos em longo 
prazo com todas as doenças neovasculares em que bevacizumabe tenha o potencial de melhorar acuidade visual. 
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INTRODUCTION
Many eye diseases and problems associated with ocular structures 
and tissues involve a single pathophysiological mechanism relating to 
increased local levels of vascular endothelial growth factor (VEGF) and 
consequently to neovascularization.1 Such diseases can include age-related 
macular degeneration, affecting 5% to 27% of health-plan beneficiaries, 
proliferative diabetic retinopathy, affecting 14.5% to 25.6% of patients 
with diabetes mellitus,2 and other less prevalent diseases, such as Stevens-
Johnson syndrome, with 2.2 to 7.1 cases per million inhabitants.3
Bevacizumab, a monoclonal antibody that binds to all VEGF iso-
forms, was developed to treat colorectal cancer,4 and its use for ocu-
lar diseases has not yet been approved by the United States Food and 
Drug Administration (FDA).5 Nevertheless, use of bevacizumab has 
been supported by Medicare in the United States since July 2006, thus 
suggesting that the information available is sufficient to allow bevaci-
zumab to be purchased and included in the management of neovascu-
lar macular degeneration.6 A growing number of researchers are mak-
ing information available regarding the use of bevacizumab for ocular 
diseases. Figure 1 demonstrates the number of papers on this subject 
that have been published since the first one in 2002.
This scenario clearly indicates the need to conduct a systematic re-
view of randomized clinical trials, in order to reduce the uncertainties 
and establish guidelines for future randomized clinical trials that test 
hypotheses about bevacizumab for patients diagnosed with ocular neo-
vascular diseases.
METHODS
Data sources and searches
The following databases were searched: Medical Literature Analy-
sis and Retrieval System Online (Medline) (1966 to June 2008), Con-
trolled Trials Register of the Cochrane Collaboration (2008, issue 2) 
and Literatura Latino-Americana e do Caribe em Ciências da Saúde 
(Lilacs) (1982 to June 2008). A general search strategy was used, with 
adaptations to the characteristics of each database, to identify studies on 
bevacizumab for ocular diseases that involved increased local levels of 
VEGF. Descriptors and synonyms for the intervention of interest (Avas-
tin®, bevacizumab) and for the clinical conditions for which this medi-
cation potentially could be indicated were used (e.g. age-related macular 
disease, corneal neovascularization, retinal angiomatous proliferation or 
angiogenic retinal diseases, among others).
Study selection
We planned to include only randomized or quasi-randomized clin-
ical trials that tested bevacizumab alone or in association with other 
strategies available. The clinical condition of interest among the individ-
uals included (of both genders, independent of ethnicity and age) was a 
diagnosis of ocular diseases or ocular conditions with the same underly-
ing pathophysiological mechanism of increased local levels of VEGF, ac-
cording to the criteria established by the authors of the primary studies, 
such as age-related macular disease, corneal neovascularization, retinal 
angiomatous proliferation or angiogenic retinal diseases, among others. 
Studies in which the analysis unit was based on the eyes were not in-
cluded, since there is evidence demonstrating an adverse event (vitritis) 
associated with bevacizumab in the contralateral eye.7
Data extraction and quality assessment
The methodological quality of the studies included was analyzed 
independently by two authors (RBA and ANA) according to the risk of 
bias (low, moderate or high risk) relating to the following items: selec-
tion bias, performance bias, detection bias and attrition bias.8
The outcome of interest for this review was visual acuity, as meas-
ured by any validated evaluation instrument (e.g. Snellen acuity charts, 
Vernier acuity, Early Treatment Diabetic Retinopathy Study chart and 
others). Adverse events, e.g. ocular or systematic hypertension, ocular 
toxicity, local inflammation, retinal detachment, vitreous hemorrhage, 
corneal abrasions, lens injury and thromboembolic events, were as-
sessed. Surrogate outcomes, such as central foveal thickness, fluoresce-
in angiography and others, were not considered in this analysis. When 
the outcome was reported in more than one paper, these results were 
combined in meta-analyses using Review Manager 5.0,9 which was de-
veloped by the Cochrane Collaboration. Dichotomous data were cal-
culated as risk ratios (RR) with 95% confidence intervals (95% CI). 
The estimated effects were combined using the random effect model,10 
which considers outliers to be related to heterogeneities of a clinical and 
methodological nature, even when they are unknown. Continuous data 
were expressed as means and standard deviations, and weighted mean 
differences (WMD) were calculated in relation needed to the 95% CI 
level. For continuous data, the numerical information needed to per-
form such analysis was composed of the total number of patients and 
the mean and standard deviation, per comparison group. For dichoto-
mous data, the numerical information needed to perform such analysis 
was composed of the total number of patients and the number of events, 
per comparison group. The reviewers grouped the data as a function of 
Figure 1. Papers reporting on bevacizumab for ocular diseases published 
per month in the PubMed database.
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The chart of cumulative relative frequency demonstrates that 50% of the studies on the application of 
bevacizumab for eye diseases were published from December 2002 to September 2007, according to 
their indexation in PubMed. The remaining 50% (237 studies) was published over a period of only nine 
months, from September 2007 to June 2008.
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co-interventions. Statistical heterogeneity between the study results was 
evaluated using the inconsistency test (I2), such that inconsistency was 
considered present when I2 > 50%.11,12
RESULTS
Description of studies with potential for inclusion
Out of the 474 studies retrieved through the search strategy, only 
nine satisfied the preestablished inclusion criteria (Figure 2). A Co-
chrane systematic review covering all anti-VEGF therapies for age-relat-
ed macular degeneration was found, but the authors had not included 
studies testing bevacizumab by the time the present systematic review 
was finished.13 One randomized study was excluded because its out-
comes did not align with the purpose of this review and because it al-
located the two eyes of each patient to different comparison groups.14 
The nine studies included in the present review yielded a total of 667 
randomized eyes, as shown in Table 1.15-23
Three studies included patients with diagnoses of diabetic macu-
lar edema.17,20,21 One study included patients with diagnoses of clini-
cally significant macular edema who had not responded to earlier subse-
quent photocoagulation therapy.15 Three studies included patients with 
Studies excluded: narrative reviews, in vitro/in situ 
studies, animal and diagnostic studies, case reports, 
retrospective case series and studies not dealing 
with the clinical condition or intervention 
of interest (n = 383)  
Prospective studies on humans that 
dealt with the clinical conditions and 
intervention of interest (n = 91)
Prospective case series (n = 77)
Prospective randomized or nonrandomized 
controlled trials on humans that dealt with 
the clinical conditions and intervention 
of interest (n = 14)
Nonrandomized controlled trials (n = 4); 
controlled trial with randomization by eyes 
instead of by patients and outcomes not 
within the scope of this review (n = 1)
Randomized controlled trials on humans 
that dealt with the clinical conditions 
and intervention of interest (n = 9)
All studies retrieved using the search 
strategy, across all databases (n = 474)
Figure 2. Flow chart of studies, from databases to inclusion in the 
systematic review.
Reference Intervention Description available in the report
15 a. bevacizumab 3 ×1.25 mg at 6-week intervals
b. bevacizumab
triamcinolone
3 × 1.25 mg at 6-week intervals
2 mg (at first session)
c. sham syringe without needle pressed 
against the conjunctiva and sclera
16 a. bevacizumab 2.5 mg × mean of 2.4 treatments
b. photodynamic therapy mean of 2.3 treatments with 
verteporfin
17 a. focal photocoagulation single dose
b. bevacizumab 1.25 mg on entry and after 6 weeks
c bevacizumab
sham injections
1.25 mg on entry
one per week
d. bevacizumab
focal photocoagulation
1.25 mg on entry and after 6 weeks
at week 3
e. bevacizumab 2.5 mg upon entry and after 6 weeks
18 a. bevacizumab 1.0 mg (single dose)
b. triamcinolone
photodynamic therapy
4.0 mg (single dose)
verteporfin (single dose)
c. triamcinolone
photodynamic therapy 
4.0 mg
verteporfin
19 a. bevacizumab 1.25 mg (single dose)
b. photodynamic therapy verteporfin (single dose)
c. bevacizumab
photodynamic therapy
1.25 mg within 1 hour after 
verteporfin
verteporfin (single dose)
20 a. triamcinolone 4.0 mg (upon entry)
b. bevacizumab 1.5  mg (upon entry)
21 a. bevacizumab 1.25 mg (upon entry)
b. bevacizumab
triamcinolone
1.25 mg (upon entry)
2.0 mg (upon entry)
c. macular laser photocoagulation single dose
22 a. bevacizumab
panretinal photocoagulation
1.5 mg, week 3
weeks 1 and 3
b. panretinal photocoagulation weeks 1 and 3
23 a. bevacizumab 1.0 mg (mean of 4.5 treatments)
b. photodynamic therapy
triamcinolone
verteporfin (mean of 1.9 treatments)
4.0 mg (mean of 1.9 treatments)
Table 1. Comparison groups and bevacizumab regimen tested in each study
diagnoses of age-related macular degeneration.18,19,23 One study tested 
bevacizumab on patients with subfoveal choroidal neovascularization 
associated with age-related macular degeneration.16 Finally, there was 
one study that included patients with diagnoses of proliferative diabetic 
retinopathy.22
With regard to the origin of the papers, two studies were conduct-
ed in Brazil,11,22 two in Iran,15,21 one in Lebanon,16 one in the United 
States,17 one in Austria,23 one in Croatia19 and one in Germany.18 None 
of these studies mentioned any financial support from pharmaceutical 
companies.
Methodological quality of the studies included
Selection bias
Four studies were considered to present low risk of selection bias, 
since they were properly conducted with regard to this factor.15,19,21,22 
All other studies were considered to present moderate risk because, al-
though their allocations were random, the methods used for generat-
ing randomization were not stated. One study allocated the eyes with 
the worst visual acuity to receive panretinal photocoagulation in asso-
ciation with bevacizumab (eight eyes), while all other eyes were treat-
ed with panretinal photocoagulation alone (eight eyes), among patients 
who were at high risk of proliferative diabetic retinopathy in both eyes. 
For this reason, this study was considered to present a high risk of sys-
tematic error.22 Separate data on the group that was randomly allocated 
were not available.
Performance bias
With the exception of three studies15,17,21 that made use of control 
groups receiving sham injections or laser, none of the other studies re-
ported any care taken to prevent performance bias.
Bevacizumab for ocular neovascular diseases: a systematic review 
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Detection bias
The majority of the studies reported that the evaluators were un-
aware of the groups to which each patient (eyes) was allocated.15,16,19,21,22 
Thus, only these five studies were considered to present a low risk of 
detection bias. All the others were considered to present a high risk of 
systematic error.
Attrition bias
None of the studies reported any substantial losses from their sam-
ples, either overall or among their comparison groups. For this reason, 
all the studies were considered to present low risk of attrition bias.
Outcome measurements
Best-corrected visual acuity 
Bevacizumab alone was shown to be better than the association of 
bevacizumab and with triamcinolone for best-corrected visual acuity 
(logMAR, change from baseline), but without a statistically significant 
mean difference (MD) (MD, 0.02; 95% CI, - 0.09 to 0.14; P = 0.70]. 
However, in one study,15 the estimate effect favored the group treated 
with bevacizumab in association with triamcinolone (MD, -0.03; 95% 
CI, -0.13 to 0.07) (Figure 3, comparison 1; two studies15,21). Compari-
sons between bevacizumab (both in association with triamcinolone and 
alone) and sham injections demonstrated statistically significant MD in 
favor of the bevacizumab groups (MD, - 0.18; 95% CI, - 0.28 to -0.08; 
P = 0.0003 and MD, - 0.15; 95% CI, - 0.26 to - 0.04; P = 0.008, re-
spectively) (Figure 3, comparisons 2 and 3; one study15). 
A statistically nonsignificant MD was observed for best-corrected 
visual acuity (logMAR, endpoint), slightly favoring the group treated 
with bevacizumab over the group treated with triamcinolone (MD, 
0.01; 95% CI, - 0.04 to 0.06; P = 0.68) (Figure 3, comparison 4; one 
study20). On the other hand, panretinal photocoagulation alone was 
better, but without statistical significance, than when combined with 
1.5 mg bevacizumab (MD, 0.02; 95% CI, - 0.12 to 0.16; P = 0.78) 
(Figure 3, comparison 5; one study22). Bevacizumab (1.25 mg) in as-
sociation with triamcinolone was also shown to be better than laser 
photocoagulation alone (MD, - 0.11; 95% CI, - 0.30 to 0.08; P = 
0.25) (Figure 3, comparison 6; one study21). For these two compari-
sons, the MD between the groups were not statistically significant. 
On the other hand, comparison between bevacizumab alone and tri-
amcinolone in association with photodynamic therapy showed a sta-
tistically significant difference in favor of bevacizumab with regard to 
the endpoint of best-corrected visual acuity (P < 0.005) in one study. 
However, the available estimated effect was not appropriate for inclu-
sion in a forest plot.18
Bevacizumab alone was shown to be better than photodynamic 
therapy for best-corrected visual acuity (logMAR, change from base-
line), with a statistically significant MD (MD, - 0.09; 95% CI, - 0.13 
to - 0.06; P < 0.00001) (Figure 3, comparison 7; one study19). Beva-
cizumab in association with photodynamic therapy was shown to be 
better than both bevacizumab alone and photodynamic therapy alone, 
with statistically significant MD (MD, -0.14; 95% CI, - 0.18 to - 0.11; 
P < 0.00001 and MD, - 0.24; 95% CI, - 0.27 to - 0.20; P < 0.00001, 
respectively) (Figure 3, comparisons 8 and 9; one study19).
Patients whose best-corrected visual acuity decreased  
(logMAR, irrespective of authors’ criteria)
There was a statistically significant greater proportion of patients 
whose visual acuity was not reduced by more than three lines in the 
group treated with bevacizumab (2/46), compared with the group 
treated with photodynamic therapy (15/44), with a risk ratio (RR) 
of 0.19 (95% CI, 0.04 to 0.86; P = 0.03). It was necessary to change 
three patients (NNT, number needed to treat) from photodynamic 
therapy to bevacizumab to avoid an additional patient presenting any 
losses in visual acuity (95% CI, 2 to 7) (Figure 4, comparison 1a; two 
studies16,23).
Patients who achieved visual acuity > three lines
The proportion of patients who presented visual acuity greater than 
three lines was higher and statistically significant in the group treated 
with bevacizumab (32/32) than in the group treated with photodynam-
ic therapy (22/30) (RR, 0.74; 95% CI, 0.59 to 0.92; P = 0.007 and 
NNT = 4; 95% CI, 2 to 10) (Figure 4, comparison 1b; one study16).
Improvements from baseline in best-corrected visual acuity
A greater proportion of patients presented increased visual acu-
ity (irrespective of authors’ criteria) in the group treated with bevaci-
zumab (29/100) than in the group treated with photodynamic ther-
apy alone or combined with triamcinolone (12/99) (RR, 0.49; 95% 
CI, 0.31 to 0.78; P = 0.003 and NNT = 4; 95% CI, 1 to 4) (Figure 
4, comparison 1c; three studies16,19,23). However, bevacizumab com-
bined with photodynamic therapy was shown to benefit more patients 
(22/55) than did photodynamic therapy alone (0/55), with RR of 
0.02 (95% CI, 0.00 to 0.36; P = 0.007 and NNT = 2; 95% CI, 2 to 
4) or bevacizumab alone (1/54), with RR of 0.05 (95% CI, 0.01 to 
0.33; P = 0.002 and NNT = 3; 95% CI, 2 to 4) (Figure 4, compari-
sons 2 and 3, respectively; one study19). There was no statistically sig-
nificant difference between focal photocoagulation alone (18/19) and 
bevacizumab alone or combined with focal photocoagulation (82/90), 
with RR of 0.96 (95% CI, 0.85 to 1.09; P = 0.54) (Figure 4, compari-
son 4; one study17).
Best-corrected visual acuity ≥ 20/40
A greater proportion of patients presented visual acuity ≥ 20/40 in 
the group treated with bevacizumab (6/30) than in the group treated 
with photodynamic therapy (0/32), without obtaining statistical sig-
nificance in estimating this effect (RR, 0.08; 95% CI, 0.00 to 1.39; 
P = 0.08 and NNT = 5; 95% CI, 3 to 25) (Figure 4, comparison 1d; 
one study16).
Adverse events
Although the adverse events potentially associated with bevacizum-
ab were of diverse types,24 the most common adverse events associated 
with bevacizumab, irrespective of whether alone or not, were: moderate 
anterior chamber reaction (19%),15 transient anterior chamber reaction 
(16%),21 iris neovascularization (11%),15 subconjunctival hemorrhage,22 
posterior vitreous detachment (15%)19 and foreign body sensation.22 
More details about other adverse events are shown in Table 2.
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DISCUSSION
Based on the primary outcome that we planned to analyze in this sys-
tematic review, the results showed that intraocular use of bevacizumab 
alone was better than photodynamic therapy (alone or combined with 
triamcinolone) for patients with subfoveal choroidal neovascularization 
associated with age-related macular degeneration, choroidal neovascular-
ization due to age-related macular degeneration and age-related macular 
degeneration alone, as reported by the authors of the primary studies. Be-
vacizumab combined with photodynamic therapy was shown to be bet-
ter than photodynamic therapy alone and bevacizumab alone for patients 
diagnosed with choroidal neovascularization due to age-related macular 
degeneration. On the other hand, photocoagulation was shown to be bet-
ter than bevacizumab (alone or combined with photocoagulation) for pa-
tients diagnosed with diabetic macular edema, but this finding was not 
statistically significant, probably because of the small sample size.
Despite the sensitivity of the search strategy used and the large 
number of published papers on this subject (474 studies), only nine 
trials satisfied the strict inclusion criteria. These studies presented the 
minimum methodological rigor appropriate for this type of question 
(i.e. regarding disease treatment) since they were clinical trials with ran-
dom allocation.25 However, it needs to be noted that the allocation of 
Figure 3. Mean best-corrected visual acuity (logMAR: endpoint and change from baseline).
Comparison Left Treatment versus Right Treatment Mean Difference Mean Difference
Study Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random, 95% CI
1. Bevacizumab + triamcinolone versus bevacizumab alone (change from baseline)
Ahmadieh 2007 -0.21 0.19 37 -0.18 0.26 41 53.7% -0.03 [-0.13, 0.07]
Soheilian 2007 -0.13 0.31 33 -0.22 0.23 37 46.3% 0.09 [-0.04, 0.22]
Subtotal (95% IC) 70 78 100.0% 0.02 [-0.09, 0.14]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.07, df = 1 (P = 0.15); I2 = 52%
Test for effect: Z = 0.38 (P = 0.70)
2. Bevacizumab + triamcinolone versus sham (change from baseline)
Ahmadieh 2007 -0.21 0.19 37 -0.03 0.24 37 100.0% -0.18 [-0.28, -0.08]
Test for effect: Z = 3.58 (P = 0.0003)
3. Bevacizumab isolated versus sham (change from baseline)
Ahmadieh 2007 -0.18 0.26 41 -0.03 0.24 37 100.0% -0.15 [-0.26, -0.04]
Test for effect: Z = 2.65 (P = 0.008)
4. Bevacizumab versus triamcinolone: best-corrected visual acuity (endpoint)
Paccola 2007 0.9125 0.0744 13 0.9233 0.0572 13 100.0% 0.01 [-0.04, 0.06]
Test for effect: Z = 0.41 (P = 0.68)
5. Photocoagulation + bevacizumab versus photocoagulation alone (endpoint)
Tonello 2007 0.29 0.1549 15 0.31 0.1587 7 100.0% 0.02 [-0.12, 0.16]
Test for effect: Z = 0.28 (P = 0.78)
6. Bevacizumab + triamcinolone versus photocoagulation alone (endpoint)
Soheilian 2007 0.67 0.38 33 0.56 0.39 33 100.0% -0.11 [-0.30, 0.08]
Test for effect: Z = 1.16 (P = 0.25)
7. Bevacizumab versus photodynamic therapy (change from baseline)
Lazic 2007 0.079 0.0937 54 -0.012 0.0956 55 100.0% -0.09 [-0.13, -0.06]
Test for effect: Z = 5.02 (P < 0.00001)
8. Bevacizumab + photodynamic therapy versus bevacizumab (change from baseline)
Lazic 2007 0.223 0.0901 55 0.079 0.0937 54 100.0% -0.14 [-0.18, -0.11]
Test for effect: Z = 8.18 (P < 0.00001)
9. Bevacizumab + photodynamic therapy versus photodynamic therapy (change from baseline)
Lazic 2007 0.223 0.0901 55 -0.012 0.0937 54 100.0% -0.24 [-0.27, -0.20]
Test for effect: Z = 13.34 (P < 0.00001)
95% CI = 95% confidence interval; Change from baseline: means of individual differences between baseline and endpoint; I2 = inconsistency or heterogeneity test, showing statistically significant (or substantial) 
heterogeneity between estimated effects from studies included, when I2 > 50%. Tau2 = variance between studies in meta-analysis based on random effects. Intersection between horizontal lines (confidence intervals) and 
horizontal line (null hypothesis) means absence of statistical significance between comparison groups. Gray lines illustrate the estimate effects (mean difference between comparison groups). Lozenge illustrates resultant 
meta-analysis.
-0.2 -0.2-0.1 -0.10
Favours Left Treament Favours Right Treament
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participants in the subgroup at high risk of proliferative diabetic retin-
opathy in both eyes was not random in one study.22 Furthermore, in 
one study,23 the nature of the interventions allowed concealment of the 
allocation and blinding of patients and therapists regarding the use of 
bevacizumab or triamcinolone, but blinding would not be operationally 
easy for photodynamic therapy. It was decided to include these studies, 
given the lack of high-quality controlled studies on the application of 
bevacizumab for treating ocular diseases at the time when this system-
atic review was implemented.
The fact that Mirshahi et al.14 was not included in this review de-
serves attention. Today, the internal validity of studies in which the eyes 
of a single patient are allocated to different groups is considered to be 
unclear. This is illustrated by the existence of contradictory studies. In-
deed, there is evidence from studying the pharmacokinetic aspects of 
bevacizumab that the possibility of contralateral effects (through sys-
temic absorption of the drug by the contralateral eye) is remote.26 On 
the other hand, there is evidence demonstrating the opposite, through 
manifestations of adverse events associated with bevacizumab in the 
Figure 4. Risk ratio for dichotomous outcomes.
95% CI = 95% confidence interval; I2 = inconsistency or heterogeneity test, showing statistically significant (or substantial) heterogeneity between estimated effects from studies included, when I2 > 50%. Tau2 = variance 
between studies in meta-analysis based on random effects. Intersection between horizontal lines (confidence intervals) and horizontal line (null hypothesis) means absence of statistically significant differences between 
comparison groups. Gray lines illustrate the estimate effects (risk ratio between comparison groups). Lozenges illustrate resultant meta-analysis.
Comparison
Outcome
Left Treatment versus Right Treament Risk Ratio Risk Ratio
Study Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI
1. Bevacizumab versus photodynamic therapy (alone or combined with triamcinolone)
a. Patients who lost their visual acuity from baseline (irrespective of authors’ definition)
Bashushur 2007 0 32 8 30 38.7% 0.06 [0.00, 0.92]
Weigert 2007 2 14 7 14 61.3% 0.29 [0.07, 1.14]
Subtotal (95% CI) 46 44 100.0% 0.19 [0.04, 0.86]
Total events 2 15
Heterogeneity: Tau2 = 0.31; Chi2 = 1.24, df = 1 (P = 0.26); I2 = 20%
Test for overall effect: Z = 2.15 (P = 0.03)
b. Best-corrected visual acuity > 3 lines
Bashshur 2007 32 32 22 30 0.74 [0.59, 0.92]
Test for effect: Z = 2.71 (P = 0.007)
c. Improved visual acuity (irrespective of authors’ definition)
Bashshur 2007 16 32 5 30 47.0% 0.33 [0.14, 0.80]
Lazic 2007 1 54 0 55 13.7% 0.33 [0.01, 7.86]
Weigert 2008 12 14 7 14 39.4% 0.58 [0.33, 1.03]
Subtotal (95% CI) 100 99 100.0% 0.49 [0.31, 0.78]
Total events 29 12
Heterogeneity: Tau2 = 0.00; Chi2 = 0.61, df = 2 (P = 0.74); I2 = 0%
Test for overall effect: Z = 2.58 (P = 0.010)
d. Best-corrected visual acuity ≥20/40
Bashshur 2007 6 30 0 32 0.08 [0.00, 1.39]
Test for effect: Z = 1.73 (P = 0.008)
2. Bavacizumab combined with photodynamic therapy versus photodynamic therapy
a. Improved visual acuity (irrespective of authors’ definition)
Lazic 2007 22 55 0 55 0.02 [0.00, 0.36]
Test for effect: Z = 2.69 (P = 0.007)
3. Bavacizumab combined with photodynamic therapy versus bevacizumab
a. Improved visual acuity (irrespective of authors’ definition)
Lazic 2007 22 55 1 54 0.05 [0.01, 0.33]
Test for effect:  Z = 3.16 (P = 0.002)
4. Photocoagulation versus bevacizumab alone or combined with photocoagulation
a. Improved visual acuity (irrespective of authors’ definition)
DRCN 2007 18 19 82 90 0.96 [0.85, 1.09]
Test for effect: Z = 0.62 (P = 0.54)
Favours Left Treatment Favours Right Treatment
0.002 0.1 1 10 500
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Adverse events
Comparison groups
Bv
% (n/N)
Pg + Bv
% (n/N)
Tr + Bv
% (n/N)
PDT + Bv
% (n/N)
Sham
% (n/N)
Pg
% (n/N)
PDT
% (n/N)
Tr
% (n/N)
PDT + Tr
% (n/N)
Anemia17 4 (4/90) - - - - 5 (1/19) - - -
Cataract progression19 7 (4/54) - - 6 (3/50) - - 0 (0/52) - -
Congestive heart failure17 1 (1/90) - - - - 0 (0/19) - - -
Death17 2 (2/90)* - - - - 0 (0/19) - - -
Elevation of blood pressure17 1 (1/90) - - - - 0 (1/19) - - -
Endophthalmitis17 1 (1/90) - - - - 0 (0/19) - - -
Foreign Body sensation22 - 13 (2/15) - - - 0 (0/7) - - -
Intraocular pressure rise15,17,20,21,23 4 (1/124) - 8 (6/70) - 0 (0/37) 0 (0/52) - 7 (1/13) 14 (2/14)
Iris neovascularization15 22 (9/41) - 0 (0/37) - 0 (0/37) - - - -
Marked anterior chamber reaction15 2 (1/41) - 3 (1/37) - 0 (0/37) - - - -
Moderate anterior chamber reaction15 19 (8/41) - 19 (7/37) - 0 (0/37) - - - -
Myocardial infarction17 2 (2/90) - - - - 0 (0/19) - - -
Peripheral vascular disease17 1 (1/90) - - - - 10 (2/19) - - -
Pigment epithelial tears19 3 (3/54) - - 0 (0/50) - - 0 (0/52) - -
Posterior vitreous detachment19 15 (8/54) - - 8 (4/50) - - 0 (0/52) - -
Progression of fibrous proliferation15 2 (1/41) - 0 (0/37) - 0 (0/37) - - - -
Subconjunctival hemorrhage22 - 47 (7/15) - - - 0 (0/7) - - -
Syncope17 1 (1/90) - - - - 0 (0/19) - - -
Transient anterior chamber reaction21 19 (7/37) - 12 (4/33) - - 0 (0/33) - - -
Transient intraocular pressure rise17 1 (1/90) - - - - 0 (0/19) - - -
Vitreous hemorrhage15 0 (0/41) - 3 (1/37) - 0 (0/37) - - - -
Worsened renal function17 3 (3/90) - - - - 0 (0/19) - - -
Table 2. Adverse events
The percentages were obtained from all studies reporting at least one event in the bevacizumab group (irrespective of whether combined with other options or alone). Bv = Bevacizumab; Pg = Photocoagulation; Tr = Triamcinolone; 
PDT = Photodynamic therapy.
*Reported causes of death were myocardial infarction and pancreatic cancer.
contralateral eye.7 Therefore, it seems sensible for the time being for 
researchers to choose types of allocation other than involving different 
treatments for each eye of the same individual.
The present scenario is that, taken together, the studies that have 
been published are still of an exploratory nature, given the diversity of 
comparisons, co-interventions, dosages and variables of interest (out-
come measurements), along with the variety of ways of reporting these 
variables. Thus, it is recommended that the specialists within this field 
should come to a consensus regarding which outcomes are relevant and 
how these should be analyzed.
It is possible to estimate the costs associated with bevacizumab. 
Bashur et al. found that an average of 2.4 treatments with 2.5 mg beva-
cizumab per patient was needed to treat persistent subretinal fluid or cys-
tic macular disease, and that 2.3 treatments with photodynamic therapy 
were needed when leakage from choroidal neovascularization was present 
on fluorescein angiography over a six-month period.16 The gross cost of 
bevacizumab is about USD 5.5 per mg (United States dollars).27 The as-
sumed cost of photodynamic therapy with verteporfrin, or Visudyne® is 
USD 3,000.00.28 The meta-analysis demonstrated that, in order to im-
prove visual acuity in one patient, 3.45 patients (29/100) would have to 
be treated with Bevacizumab and 8.25 patients (12/99) with photody-
namic therapy (Figure 4, comparison 1c). The estimated expense would 
be USD 113.85 for bevacizumab and USD 56,925.00 for photodynamic 
therapy. Considering the findings of Brown et al.,29 an average of 11 treat-
ments of 0.5 mg ranibizumab per patient would have to be administered, 
at a cost of USD 3,900.00 per mg. 27 To improve visual acuity, defined as 
≥ 15 letters at 12 months, 2.48 patients (56/139) would have to be treat-
ed with ranibizumab. The estimated cost would be USD 53,196.00.
Results from future trials may provide more information about 
the wide variety of types of outcome measurements (including adverse 
events), comparisons and co-interventions, such as photodynamic ther-
apy, laser photocoagulation, triamcinolone and vitrectomy.
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